First Wave BioPharma Inc
NASDAQ:ENTO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
R
|
Ramssol Group Bhd
KLSE:RAMSSOL
|
MY |
|
N
|
Nishimatsu Construction Co Ltd
TSE:1820
|
JP |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (13.3), the stock would be worth $-277 (9 819% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -0.1 | $2.85 |
0%
|
| Industry Average | 13.3 | $-277 |
-9 819%
|
| Country Average | 14.4 | $-299 |
-10 591%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
First Wave BioPharma Inc
NASDAQ:ENTO
|
9.6m USD | -0.1 | -0.1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -194 446.1 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
369.5B USD | 14.6 | 88.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188.3B USD | 14.2 | 24.4 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
171.9B USD | 12.6 | 20.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -581 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.7B USD | 21 | 28 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.9B USD | 12.9 | 17.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
44B EUR | 43.7 | 40.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.3B AUD | 10.9 | 32.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -66.6 | -61.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10 |
| Median | 14.4 |
| 70th Percentile | 21.5 |
| Max | 1 767 274.1 |
Other Multiples
First Wave BioPharma Inc
Glance View
First Wave Biopharma, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of non-systemic therapies for the treatment of gastrointestinal diseases. The company is headquartered in Boca Raton, Florida and currently employs 17 full-time employees. The company went IPO on 2016-10-11. The firm is focused on developing its pipeline of gut-restricted GI clinical product candidates, including niclosamide, which is an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, which is a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The firm is advancing two separate clinical programs of niclosamide formulations, both of which are in Phase II clinical trials, including FW-COV for Severe Acute Respiratory Syndrome Coronavirus 2 GI infections, and FW-UP for ulcerative proctitis and ulcerative proctosigmoiditis. The adrulipase programs is focused on the development of an oral, non-systemic, biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis.
